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Abstract 
Purpose/Background 
Clozapine is the gold standard in treatment resistant schizophrenia(TRS). We sought to 
review data on several inflammatory effects associated with clozapine, specifically interstitial 
nephritis, hepatitis and pancreatitis. 
 
Methods/Procedures 
We conducted a systematic review to identify studies, published up until December 2017, 
describing clozapine-induced hepatitis, nephritis and pancreatitis. The primary objective was 
to characterise the clinical characteristics associated with each of the specific inflammatory 
reactions to clozapine.  
Findings/Results 
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We identified 42 cases of inflammatory reactions associated with clozapine treatment- 20 
cases of clozapine induced hepatitis, 11 cases of nephritis, and 11 of pancreatitis. The mean 
age was 38.8(SD=11.9) years. The mean dose of clozapine used was 252.4(SD=133.7) mg. 
Time to onset of pancreatitis (17.9(SD=11.2)(range 4-35)days) was shorter than that for 
hepatitis (34.2 (SD=20.1)(range=12-90)days) and nephritis (27.9(SD=27.0)(range=8-
90)days), but was not statistically significant (F=2.267,p=0.117). The mean time to recovery 
was shorter for cases of pancreatitis (15.7(SD=18.4)days) compared to cases of hepatitis 
(25.9(SD=16.5)) and nephritis (24.5(18.9)days). Three cases with hepatitis died. Seven of 
the cases had a clozapine rechallenge (hepatitis (n=3), nephritis (n=1), pancreatitis (n=3)), 
with five having a recurrence at a mean onset of 3.5(SD=2.5)days(range=1-7 days); two 
hepatitis cases were successfully rechallenged.  
Implications/Conclusions 
Clozapine-induced hepatitis, nephritis and pancreatitis are uncommon adverse events, 
reflected in the paucity of case studies in the literature.	  Early recognition of the signs and 
symptoms of clozapine associated hepatitis, nephritis and pancreatitis is important, as when 
identified, clozapine should be urgently discontinued. Clozapine is associated with evidence 
of benign inflammatory processes- the extent to which hepatitis, and other inflammatory 
reactions, may be on a continuum with these more benign and self-limiting reactions is 
unclear, and this can only be resolved by prospectively following cohorts of clozapine-treated 
patients.  
Keywords: adverse event; side effect; antipsychotic; schizophrenia; treatment-
resistant 
 
 
 
Introduction 
Clozapine is the most effective medication for treatment resistant schizophrenia (TRS). 1 As 
a result, it occupies a unique position in the management of schizophrenia and other 
psychotic disorders. However, the use of clozapine is limited by the occurrence of adverse 
events. Some of the more serious adverse events associated with clozapine, such as 
agranulocytosis and myocarditis are idiosyncratic and have similarities to hypersensitivity 
reactions.2-4 
Clozapine is associated with nonspecific inflammatory responses in the early weeks of 
treatment, including benign fever, raised inflammatory markers such as C-reactive protein,  
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and eosinophilia. 5, 6 Less commonly, inflammatory disorders such as myocarditis, 
pericarditis, serositis, interstitial nephritis, hepatitis and pancreatitis have been reported.  
The demographic and clinical profile of these clozapine treated patients who develop 
inflammatory disorders has yet to be described in a sufficiently large sample, which has 
prevented clinicians from adopting an evidence-based approach to their diagnosis and 
management. The present study aims to address this issue through a systematic review of 
cases reported in the literature. Previous reviews have focused on cardiotoxicity, including 
pericarditis and myocarditis,7 and serositis,8 associated with clozapine treatment and these 
effects will not be revisited in this review.  
Aims 
To gain a better understanding and awareness of clozapine inflammatory adverse effects, 
we conducted a systematic review to identify clinical features associated with clozapine 
associated hepatitis, nephritis and pancreatitis. 
 
 
Methods 
We performed a literature search to identify peer-reviewed articles of interventional and 
observational studies; case series and case reports, published until December 2017, 
investigating or describing clozapine associated hepatitis, nephritis, and pancreatitis.  This 
systematic review was conducted in accordance with the Preferred Reporting Items for 
Systematic Reviews and Meta-analyses (PRISMA) standard. 9 
Inclusion criteria 
Studies and case reports of patients (no age restrictions) describing a clozapine associated 
hepatitis, nephritis, or pancreatitis, including patients who developed such an episode during 
rechallenge. We included clinically diagnosed interstitial nephritis in which evidence of acute 
renal failure and/or acute kidney injury were recorded with concurrent evidence of an 
inflammatory response, as in such cases renal biopsy is not required to confirm the 
diagnosis. 10 
Exclusion-criteria 
Studies were excluded: if there was evidence of clozapine associated myocarditis; if an 
alternative cause for the inflammatory disorder was documented; if the inflammatory disorder 
appeared to have occurred secondary to a different clozapine adverse event (e.g. clozapine 
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induced hypertriglyceridemia); if there were insufficient clinical or laboratory data to permit 
further evaluation of the report. 
Information sources and searches 
Two independent reviewers (HAK and JL) performed an electronic search using PubMed, 
Medline, Scopus, EMBASE and Google Scholar from inception until December 2017. The 
following search terms were used, alone and in combination: clozapine AND hepatitis or 
nephritis or pancreatitis. In addition, the reference lists of the retrieved articles and relevant 
review articles were examined for further reports.  
Study selection and exclusion 
All extracted reports were examined independently by two authors (HAK and JL) and a list of 
full text articles established. Authors were contacted for clarification where necessary.  
The study selection process, search results, and reasons for exclusion are given in figure 1. 
The initial search yielded 127 references. After checking titles and abstracts, 59 full texts 
were screened and 41 of these (42 patients) were included for data extraction. All were case 
series or reports; no interventional or observational studies were identified. 
Data extraction 
The primary objective was to characterise the clinical characteristics associated with each of 
the specific inflammatory disorders, including the time to recovery and mortality associated 
with the systemic inflammatory disorder.  
Where available, we extracted demographic data (gender, age and ethnicity) and relevant 
laboratory data including: White cell counts (WCCs), neutrophil counts, lymphocyte counts, 
eosinophil counts, C-Reactive Protein (CRP), erythrocyte sedimentation rate (ESR), renal 
function tests (serum creatinine levels), Liver Function Tests (Alkaline phosphatase (ALP), 
Aspartate Aminotransferase (AST), Gamma-glutamyl transpeptidase (GGT)) and serum 
bilirubin; amylase level, lipase level, and urinalysis. We recorded information on: timing of 
the onset of the inflammatory disorder relative to clozapine initiation, clozapine dose used, 
plasma clozapine and norclozapine concentrations, concurrent medications used 
concomitant disease, and smoking. We examined presenting signs and symptoms, 
management, time to recovery, and mortality associated with the inflammatory disorder.  
Results  
Demographic and clinical characteristics of all included cases of clozapine induced 
systemic inflammatory disorders. 
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There were 41 qualifying reports, all of which were case reports. In total 42 patients were 
identified who developed a clozapine associated hepatitis, nephritis, or pancreatitis. 
We identified 20 cases of clozapine induced hepatitis,11-3011 cases of nephritis,31-41 and 11 of 
pancreatitis.42-52 Demographic and clinical characteristics of all identified cases are shown in 
table 1.  
Forty eight percent of the cases were of White ethnicity (n=11), 44% were of Asian ethnicity 
(n=10), and one was of Black ethnicity and one of mixed ethnicity. Most the cases identified 
had a diagnosis of schizophrenia (76%; n=32). Fourteen percent had a diagnosis of 
schizoaffective disorder (n=6), with 3 cases of bipolar affective disorder and one case of 
psychosis in Parkinson’s disease. 
Clinical characteristics of all cases  
The mean dose of clozapine used was 252.4mg (SD=133.7). In three cases (two hepatitis 
and one pancreatitis case respectively) plasma clozapine concentrations were recorded, and 
were above the therapeutic range in all cases, with a mean plasma clozapine concentration 
of 0.87 mg/L (range 0.831-0.910mg/L). 17, 24, 43 In two of the cases plasma norclozapine was 
recorded with a mean level of 0.23 mg/L (range 0.21-0.24 mg/L) The mean duration of 
clozapine use prior to the onset of the systemic inflammatory disorder was 28.3 (SD=21.0) 
days (median=24.5 days; range 0-90 days).  
Where concomitant medication was reported, 6 out of 10 patients with nephritis, 1/4 with 
hepatitis, and 1/3 with pancreatitis were concurrently treated with lithium carbonate; 6/10 
with nephritis, 2/4 with hepatitis, and 1/3 with pancreatitis were concurrently treated with 
sodium valproate. 
Fever (>38 °C) was reported in ninety percent of cases (n=18/20), eosinophilia in 86% 
(n=19/22). Twelve cases had multiple internal organ involvement. (n=5 with hepatitis (liver 
and respiratory involvement (n=4); liver, kidney and respiratory involvement (n=1)); n=4 with 
nephritis (kidney and respiratory involvement in all 4 cases); and n=3 with pancreatitis 
(pancreatic and liver involvement (n=2); and pancreatic and kidney involvement (=1)).  
CRP was reported in 9 cases, all of which were raised (n=2 hepatitis; n=4 nephritis; n=3 
pancreatitis).  The mean CRP level was 116.9 (SD=94.5) (range 7.0-297.4) mg/L. Only three 
reports commented on cutaneous involvement, with two cases having a skin rash. The 
presence or absence of lymphadenopathy or atypical lymphocytes was not determined in 
any of the cases.   
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Recovery and mortality 
The mean time to recovery in 27 cases was 23.0 (SD=17.4) days (median=17 days; 
range=3-62 days). The duration to recovery for those treated with clozapine and valproate 
(mean=16.7 (SD=3.8) days) was longer compared to those not co-treated with valproate 
(mean=9.0 (SD=5.8) days; t=1.964, p=0.107). Clozapine associated pancreatitis had a non-
statistically significant shorter time to recovery compared to hepatitis cases (mean difference 
-16.3 days, p=0.097, 95%CI: -34.9-2.4) and nephritis cases (mean difference -10.8 days, 
p=0.490, 95%CI: -31.2—11.2). 
Death was reported in three cases of clozapine induced hepatitis. 18, 26, 29  
Clozapine rechallenge 
Seven of the cases underwent a clozapine rechallenge (hepatitis n=3, 11, 12, 15 nephritis n=1 
35, pancreatitis n=3  45, 50, 51). Five of the cases had a recurrence of the incident inflammatory 
disorder, at a mean onset of 3.5 (SD=2.5) days (range=1-7 days) which was significantly 
shorter than those who were treated with clozapine for the first time (mean=27.0 (SD=19.0) 
days (range=0-90 days)) (t=-2.418, p<0.019). The mean time to recurrence in pancreatitis 
rechallenge was 3.7 (SD=3.1) days (range 1-7); the time to recurrence in a single nephritis 
case was 3 days.   Two of the cases of clozapine associated hepatitis were successfully 
rechallenged. 12, 15 
Treatment of nephritis 
The most comprehensive treatment documentation was recorded in nephritis cases. Of 
those with clozapine associated nephritis, 46% (n=5/11) were treated with steroids (n=2 with 
methylprednisolone 1g/day for 3 days, followed by oral prednisolone), with prednisolone 
used in all five cases (dose range 25-30mg/day in those in which it was recorded); and 27% 
(n=3/11) receiving haemodialysis.  
Discussion 
Our review findings provide the largest synthesis of cases of clozapine associated hepatitis, 
nephritis and pancreatitis. The presenting symptoms and signs in most cases were vague, 
and related to internal organ involvement. Most cases presented with eosinophilia and fever, 
along with raised transaminases in hepatitis, raised creatinine in nephritis and raised lipase 
(and/or amylase) in pancreatitis. Fever was seen in the majority of cases, along with raised 
CRP and eosinophilia, all indicative of hypersensitivity. CRP was elevated in all cases in 
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which it was reported, but the majority of cases did not report CRP levels.   More than one 
organ was involved in 47% of cases.  
Clozapine associated hepatitis 
Liver involvement was characterised by fever, abdominal pain and non-specific symptoms 
such as nausea, and lethargy, with jaundice occurring in a minority of cases. All cases had 
clinically significant elevated transaminases (ALT and/or AST > 3 fold above the upper limit 
of normal(ULN) 53), and evidence of eosinophilia, with over 50% with elevated serum 
bilirubin (> 2 fold above the ULN). The onset of hepatitis was within 8 weeks of clozapine 
initiation in all but three cases (onset at 60, 63 and 90 days respectively) with a mean time to 
onset of 34.2 days. The average time to recovery was 25.9 days. Fifty percent of hepatitis 
cases had other internal organ involvement, and it was associated with death in three cases. 
The mean ALT value of 629 U/L is consistent with findings in drug induced liver failure in 
which the elevation in ALT and/or AST at 500-600 IU/L is less marked when compared to 
other causes, such as paracetamol toxicity, or viral hepatitis (such as hepatitis A or B).  54 
Drug induced liver injury is responsible for approximately  2- 13.9 cases per 100,000 people 
per year.55, 56  Previous studies comparing differential effects of antipsychotics on liver 
function, identified that clozapine was most frequently associated with abnormal LFTs. 57-59 A 
systematic review identified a median rate of clozapine associated clinically significant 
elevations in LFTs (> 2 fold ULN of AST and/or ALT) of 16.7%, though this was not 
equivalent to severe liver injury in the majority.59 The mechanism for benign changes in LFTs 
relating to clozapine use, may be related to indirect mechanisms such as comorbid alcohol 
use and alcohol fatty liver changes, weight gain and metabolic syndrome, 60 whereas the 
more severe inflammatory response identified in this review is postulated to be an immune 
mediated hypersensitivity phenomenon. 6, 59  
 
Clozapine associated nephritis 
Nephritis was characterised by fever, gastrointestinal symptoms, tachycardia and urinary 
difficulties. The classic clinical triad of rash, fever, and eosinophilia was not present, with a 
rash not documented in any cases, suggesting that clozapine-associated nephritis differs 
from classical nephritis. Creatinine was raised in all cases, as was CRP (reported in four 
cases only) and proteinuria was seen in most cases. The onset of nephritis was within 3 
weeks of clozapine initiation in 73% of cases, with the other 3 cases having onset at 45-90 
days. The time to recovery was less than 4 weeks for all but one, in which the time to 
recovery was 61 days.  
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Of suspected clozapine adverse events reported to the United Kingdom Medicines and 
Healthcare products Regulatory Agency (n=26,000), 10 were of acute interstitial nephritis 
and 31 of acute renal failure,35 indicating that it is a low prevalence event, which is indicated 
by the low number of cases identified in our review. 
Clozapine associated pancreatitis 
Pancreatitis was characterised by fever, abdominal pain, and distension, with nausea and 
vomiting. All cases had abnormal amylase and/or lipase measures, and raised CRP. Twice 
as many people had raised lipase compared to amylase. Clozapine associated pancreatitis 
was identified earlier than the onset of nephritis or hepatitis, with a mean onset of 18 days 
(all cases with onset within 5 weeks of clozapine initiation), although this may reflect the fact 
that pancreatitis was the most symptomatic of the three disorders. In pancreatitis lipase and 
amylase tend to rise within the first few hours of symptom onset, with lipase remaining 
elevated for longer than amylase levels.61 It is important to note that in up to 25% of cases 
serum amylase or lipase levels will not be elevated, necessitating need to consider imaging 
studies if the clinical presentation is suggestive of pancreatitis. 61  
In our review, clozapine associated pancreatitis had a shorter duration of recovery (15.7 
days) compared to hepatitis and nephritis cases. A Swedish Nationwide database study 
identified an increased risk of pancreatitis with antipsychotic use, though this was not 
increased with clozapine or olanzapine use (OR 0.9 (0.6-1.4).62 Drug induced pancreatitis is 
responsible for up to 2% of acute pancreatitis, necessitating consideration for alternative 
causes.63 Alcohol abuse is common in schizophrenia, and is a potential aetiology for 
clozapine associated pancreatitis, associated with up to 30% of pancreatitis cases in the 
general population63. Assessment for hyperglycaemia and hypertriglyceridaemia are 
indicated in cases of clozapine induced pancreatitis, as both are risk factors for pancreatitis 
and can be raised early in the course of clozapine use. 64-66 In a pharmacovigilance survey 
and literature review, 16 clozapine associated pancreatitis cases were identified occurring in 
the context of recently diagnosed hyperglycaemia67. If indicated, appropriate treatment of 
hyperglycaemia with insulin therapy should be initiated, with antibiotic therapy indicated if 
infection is identified.  A systematic review of the FDA’s MedWatch database found that 
sodium valproate was used in 34% (n=22/64) of clozapine associated pancreatitis cases,67 
while 1 case from 3 pancreatitis cases were treated with sodium valproate in our review. 
Clozapine dose effect 
A casual association between clozapine and hepatitis, nephritis and pancreatitis is strongly 
suggested by timing of the adverse reaction, and recovery on discontinuation of clozapine. 
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No conclusions can be drawn about a dose-effect relationship, as the systemic inflammatory 
process occurred in most cases at a clozapine dose of < 400mg daily. However, the mean 
plasma concentration of clozapine was 0.9 mg/L in 3 cases in which it was recorded, with all 
those cases treated with 300mg daily of clozapine. All cases in which plasma clozapine 
concentration was recorded had evidence of supratherapeutic plasma clozapine 
concentrations. This may have been artefactual, related to impaired clozapine metabolism 
due to hepatic dysfunction or impaired elimination.68 Alternatively, such elevated clozapine 
plasma levels may be a contributory factor to clozapine systemic inflammatory disorders.  
Clozapine rechallenge following clozapine-associated inflammatory reactions 
There have been a few reported cases of clozapine rechallenge after an episode of 
clozapine associated hepatitis (n=3), nephritis (n=1) or pancreatitis (n=3).  
Rechallenge following clozapine associated hepatitis 
Two of the clozapine associated hepatitis cases were successfully rechallenged with 
clozapine.  In the first, clozapine was titrated to 300mg daily (during the initial clozapine trial 
the patient was treated with 175mg daily in combination with sodium valproate 1000mg twice 
daily) with no recurrence of hepatitis 15 at 36 months follow up. Sodium valproate was not 
used during rechallenge, suggesting that it may have contributed to the incident hepatitis. In 
the other successful clozapine rechallenge following hepatitis, LFTs were monitored three 
times weekly, and rose to ALT 208U/L, AST 109U/L at day 20 while treated with clozapine 
500mg/day. Clozapine (concurrent medication use not recorded) was continued at a reduced 
dose of 400mg /day and LFTs normalised, with clozapine maintained at 9 months follow up 
with normal LFTs. 12  
Rechallenge following clozapine associated nephritis 
One case of clozapine induced nephritis was rechallenged with clozapine. In this 25 year 
old, there was a recurrence of nephritis, with fever, tachycardia, markedly raised CRP (197 
mg/L) and a rising creatinine, all occurring within 3 days of clozapine (dose 25mg/day) 
rechallenge. 35   
Rechallenge following clozapine associated pancreatitis 
Three cases of clozapine associated pancreatitis were unsuccessfully rechallenged with a 
recurrence of pancreatitis within 7 days in all cases.  
In the first, clozapine was reinitiated 18 months after the index episode (time to onset 27 
days). 51 Prior to clozapine rechallenge there were two separate records of mildly elevated 
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lipase (299 IU/L and 273IU/L). Clozapine 12.5mg twice daily was administered for one day 
before the onset of right upper quadrant pain, nausea and vomiting. A serum lipase of 546 
IU/L and a mild eosinophilia were seen. Clozapine was discontinued and symptoms did not 
recur, with serum lipase returning to pre- clozapine levels in 3 weeks.  
In the second rechallenge, clozapine was started 7 days after the initial clozapine associated 
pancreatitis.50 Three days after clozapine initiation, the patient had abdominal pain and 
distension, and ileus, with a recorded serum amylase of 379 IU/L and lipase 485 IU/L. 
Clozapine was discontinued, and over the next 7 days symptoms gradually resolved and 
serum lipase and amylase levels normalised. 
In the final case, clozapine was reinitiated at an unspecified time after the index episode 
(time to onset 30 days and a plasma clozapine concentration of 831mg/L).45 One week after 
clozapine initiation and at a dose of 100mg daily, there was an elevation in glucose and 
pancreatic enzymes (level not specified, though they were less marked than index episode 
lipase level of 759 IU/L). Clozapine was discontinued and the patient was treated with 
antibiotics and insulin regimen.  
In the five unsuccessful rechallenge cases, the onset of the systemic inflammatory disorder 
was earlier than that seen in people treated with a first clozapine trial, consistent with a 
hypersensitivity reaction.  
Relationship with nonspecific inflammatory reactions to clozapine 
It has been shown that clozapine treatment is frequently associated with transient and 
apparently benign pyrexia, often accompanied by eosinophilia and elevations in C-reactive 
protein and other non-specific inflammatory markers, early in the course of treatment. 5, 6  
This inflammatory response usually resolves spontaneously despite continuation of 
clozapine treatment. Other studies have shown asymptomatic and benign elevations in 
transaminases and ALP (>2 fold above upper limit of normal) in up to 40% of clozapine 
treated patients, 58 which also seem to be transient, with 60% normalising within 13 weeks 
despite continued clozapine treatment. 57  
We therefore consider it probable that some, or even the majority, of patients with non-
specific inflammatory responses may also have transient elevations in liver enzymes, which 
are not identified since liver function tests are rarely ordered. The extent to which hepatitis, 
and other inflammatory reactions, may be on a continuum with these more benign and self-
limiting reactions is unclear, and this can only be resolved by prospectively following cohorts 
of clozapine-treated patients.  
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Limitations 
Limitations include the retrospective review of case reports, and the large amount of missing 
data in the included reports, inconsistencies between laboratory norms for the relevant 
investigations, and inconsistent reporting of signs and symptoms. There were no controlled 
studies available, and there is a need for caution in interpreting data relating to case reports 
and case series. 69 Case reports alone cannot provide an accurate or quantitative estimate 
of the risk for complications or death associated with a drug or treatment intervention such 
as this. Publication bias may have affected the cases reported: for example, successful 
rechallenge may have been more likely to have been reported than failed rechallenge. 
Further, details on clinical outcome and therapeutic interventions was often lacking in the 
included case reports. Finally, we restricted our search to peer-reviewed reports, ensuring 
that all included studies have been peer reviewed, but meaning that we may have missed 
studies from the ‘grey literature’. It is likely that clozapine associated hepatitis, pancreatitis 
and nephritis occurs more frequently than is indicated in our review and which may be 
reflected in increased content in the ‘grey’ literature. 
Implications for clinical practice 
Notwithstanding the limitations above, this review gives an indication of the clinical picture 
associated with each of the individual disorders.  The results have some implications for 
practice.  
Clinicians should be aware of the potential for hepatitis, nephritis or pancreatitis with 
clozapine use which should prompt withdrawal of clozapine if it is identified as the offending 
agent, with referral to general medical teams if required. It seems prudent to measure 
baseline renal function and LFTs as part of a pre-clozapine work up, so that any subsequent 
elevation can be quantified. While there seems insufficient evidence to support the routine 
monitoring of LFTs (transaminases), renal function, pancreatic enzymes in standard 
monitoring protocols, any emergence of fever, eosinophilia or markedly raised CRP (> 50 
mg/L), should be followed with checks of LFTs, renal function, and serum lipase, to ensure 
that no covert inflammatory process is occurring.  
In our review, there was insufficient data provided in the identified cases to draw any 
inferences about the treatment of the clozapine associated inflammatory disorder.  
 
Rechallenge 
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Successful clozapine rechallenge has been implemented with haematopoietic support in 
clozapine agranulocytosis, 70 but in systemic inflammatory disorders, there appears to be a 
high risk of recurrence where there is evidence of autoimmune involvement, with fever and 
eosinophilia and multiorgan involvement.  We found insufficient information to make 
inferences about rechallenge other than the observation that successful rechallenge is 
possible in some cases. Clinicians need to remain aware of the potential for a more rapid 
onset of symptoms following a rechallenge.  
 
Conclusion 
Our systematic review confirms that clozapine associated inflammatory disorders are not 
commonly reported in the literature, likely a reflection of their low incidence. The occurrence 
of abnormal blood parameters and /or symptomatic liver, kidney, or pancreatic injury should 
prompt withdrawal of clozapine and full assessment. The discontinuation of clozapine 
remains the cornerstone of management in such cases with most cases reaching full 
recovery following discontinuation. Future research might focus on the underlying 
mechanisms of drug hypersensitivity reactions, and their relationship to more benign and 
transient reactions, to better understand the aetiology of clozapine associated systemic 
inflammatory disorders and other hypersensitivity reactions.   
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 Table 1 
Baseline characteristics of individual case reports of clozapine induced hepatitis, 
nephritis and pancreatitis (total n=42) 
 All cases Hepatitis Nephritis Pancreatitis 
Gender 21 males 
21 females 
9 males 
11 females 
6 males 
5 females 
6 males 
5 females 
Mean age (SD) years 38.8 (11.7) 
(range 17-73) 
40.4 (9.9) 35.9 (12.6) 38.7 (14.6) 
Mean clozapine dose 
(mg) (SD) 
252.4 (133.7) 298.7 (92.2) 211.4 (179.7) 213.6 (127.7) 
Mean plasma 
clozapine/norclozapine 
concentration (mg/L) 
(SD) 
0.87 (0.04)/ 
0.23 (0.02) 
0.905 (0.01) 
(n=2) /0.21  
N/A 0.831/0.24 (n=1) 
 
16	  
	  
Mean time to onset 
(days) (SD) (range) 
F=2.267, p=0.117 
28.3 (21.0) (0-
90) 
34.2 (20.1), 
(12-90) 
27.9, (SD=27.0), (8-
90) 
17.9 (11.2), (4-
35) 
Clinical presentation  Fever: 88.9% 
Lethargy: 
33.3% 
Jaundice: 
22.2% 
Abdominal 
pain: 22.2% 
Nausea: 22.2% 
Fever:100% 
Tachycardia: 36.4% 
Vomiting:27.3% 
Diarrhoea :27.3% 
Nausea: 18.2% 
Urinary difficulty 
:18.2% 
 
Fever:75% 
Abdominal 
Pain:46.6% 
Nausea: 23.1% 
Vomiting: 23.1% 
Abdominal 
distension:15.4% 
 
Laboratory data  Raised CRP 
100 % 
Mean ALT 
level: 628.8 
(SD=571.1) 
IU/L 
ALT > 3 fold 
upper limit of 
normal(ULN): 
85.0% 
(n=17/20) 
Mean AST 
level: 318.7 
(SD=266.8) 
IU/L 
AST >3-fold 
ULN: 72.2% 
(n=13/18) 
Raised bilirubin 
> 2 ULN: 9/16 
(56.3%) 
Raised 
eosinophils: 
100% 
Raised CRP:100 % 
(range=58.0-
294.0mg/L) 
 
Proteinuria: 72.7% 
 
Mean Serum 
creatinine: 499.5 
(371.9) umol/L  
 
Raised eosinophils: 
85.7% 
Raised 
CRP:100% 
(range=7.0-
82.5mg/L) 
 
Mean Amylase 
level:344.8 U/L 
Mean Lipase 
Level: 1643.3 
(1628.3) U/L 
 
Raised amylase 
> 3 ULN: 31% 
(n=4/13) 
Raised lipase > 
3 ULN: 78% 
(n=7/9) 
Raised 
eosinophils:60% 
Mean time to recovery 
(days) (SD) (range) 
F=0.822, p=0.451 
23.0 (17.4) (3-
62) 
 
25.9 (16.5), (7-
62) 
24.5 (18.9), (10-61) 15.7 (18.4), (3-
56) 
 
17	  
	  
ULN= Upper limit of normal 
Table 2 Summary of findings 
We identified 42 cases of clozapine associated hepatitis (n=20), nephritis (n=11) and 
pancreatitis (n=11) 
The time to onset was 19 days for pancreatitis, 28 days for nephritis and 31 days for 
hepatitis  
No clozapine dose effect was identified 
Time to recovery was shortest for clozapine associated pancreatitis (16 days) compared to 
hepatitis (26 days ) and nephritis (25 days)  
Three cases of clozapine hepatitis were fatal 
Recurrence occurred in two pancreatitis cases, 1 hepatitis case and 1 nephritis case, with 
two hepatitis cases successfully rechallenged 
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